Biblio Discovery — Demo Discovery Service

9 hasil untuk "Matthew Matasar"

Menampilkan 1–9 · 2,66 detik · RSS

  1. Artikel Jurnal

    Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL

    Jon E. Arnason; Matthew Matasar; Stefano Luminari dkk.

    Blood Advances, Vol. 9 No. 23 · 2025 · Inggris · DOAJ Scopus

    Abstract: Odronextamab, a CD20×CD3 bispecific antibody, demonstrated robust efficacy and durable responses, with a generally manageable safety profile, in patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 2 ELM-2 study. This…

  2. Artikel Jurnal

    Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

    Paola Ghione; Salma Ahsanuddin; Efrat Luttwak dkk.

    Haematologica, Vol. 109 No. 1 · 2023 · Inggris · DOAJ Scopus

    Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with fluorodeoxyglucose, which may demonstrate residual avidity despite a complete response. We analyzed clinical data of…

  3. Artikel Jurnal

    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    Hervé Tilly; Franck Morschhauser; Laurie H. Sehn dkk.

    New England Journal of Medicine · 2021 · Inggris · OpenAlex Scopus

    BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously…

  4. Artikel Jurnal

    Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma

    Erel Joffe; Manik Uppal; Serena Zheng dkk.

    Haematologica, Vol. 999 No. 1 · 2025 · Inggris · DOAJ Scopus

    Most patients diagnosed with mantle cell lymphoma (MCL) experience extended remissions following frontline chemoimmunotherapy, yet with with extended follow-up, relapses seem nearly inevitable. This study aimed to define the genomic landscape of MCL at diagnosis and relapse and investigate the…

  5. Artikel Jurnal

    Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium

    John S. Wang; Brandon L. Ellsworth; Megan Melody dkk.

    Blood Advances, Vol. 10 No. 3 · 2026 · Inggris · DOAJ Scopus

    Abstract: Chimeric antigen receptor T-cell (CART) therapy has transformed the management of relapsed and refractory large B-cell lymphoma (LBCL), but real-world outcomes data is needed to confirm the benefits seen in clinical trial settings. We performed a multicenter retrospective analysis…